Phase Ib/II investigator-sponsored trial evaluatin the safety and preliminary efficacy of WEE1 inhibitor Debio 0123 in combination with Sacituzumab Govitecan (Trodelvy®) in triple-negative and HR+/HER2- advanced breast cancer.

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 02 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Debio 0123 (Primary) ; Sacituzumab govitecan (Primary)
Indications Advanced breast cancer; HER2 negative breast cancer; Triple negative breast cancer
Focus Adverse reactions
Acronyms WIN-B

Most Recent Events

25 Feb 2025 According to Debiopharm media release , WIN-B trial is sponsored by MEDSIR and fully funded by Debiopharm. Gilead Sciences, Inc. (Gilead) is providing supply of Trodelvy.
31 May 2024 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight